Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Keros Therapeutics, Inc. (KROS) since 2020 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Keros Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1664710.
Total stock buying since 2020: $61,404,057.
Total stock sales since 2020: $57,736,277.
Total stock option exercises since 2020: $751,935.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 934,258 | $9,212,718 | 0 | $0 | 49,367 | $14,810 |
| 2024 | 0 | $0 | 500,000 | $22,005,000 | 0 | $0 |
| 2023 | 0 | $0 | 40,000 | $1,811,600 | 44,000 | $641,920 |
| 2022 | 0 | $0 | 127,343 | $5,969,933 | 94,092 | $68,921 |
| 2021 | 0 | $0 | 552,442 | $27,949,744 | 114,709 | $26,284 |
| 2020 | 2,624,088 | $52,191,339 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-04 | 934,258 | $9,212,718 | 0 | $0 | 49,367 | $14,810 |
| 2024-08 | 0 | $0 | 500,000 | $22,005,000 | 0 | $0 |
| 2023-11 | 0 | $0 | 40,000 | $1,811,600 | 40,000 | $640,000 |
| 2023-04 | 0 | $0 | 0 | $0 | 4,000 | $1,920 |
| 2022-07 | 0 | $0 | 47,950 | $1,438,500 | 47,950 | $14,384 |
| 2022-06 | 0 | $0 | 0 | $0 | 14,400 | $4,320 |
| 2022-05 | 0 | $0 | 5,300 | $229,755 | 5,300 | $1,590 |
| 2022-04 | 0 | $0 | 15,842 | $971,459 | 15,842 | $45,447 |
| 2022-03 | 0 | $0 | 2,650 | $141,623 | 2,650 | $795 |
| 2022-02 | 0 | $0 | 2,650 | $138,640 | 2,650 | $795 |
| 2022-01 | 0 | $0 | 52,951 | $3,049,956 | 5,300 | $1,590 |
| 2021-12 | 0 | $0 | 50,301 | $2,717,896 | 2,650 | $794 |
| 2021-11 | 0 | $0 | 79,451 | $3,808,015 | 31,800 | $9,540 |
| 2021-10 | 0 | $0 | 47,651 | $1,862,357 | 0 | $0 |
| 2021-09 | 0 | $0 | 95,302 | $3,949,314 | 0 | $0 |
| 2021-08 | 0 | $0 | 0 | $0 | 1,293 | $387 |
| 2021-07 | 0 | $0 | 47,652 | $1,985,972 | 0 | $0 |
| 2021-06 | 0 | $0 | 28,236 | $1,422,832 | 6,500 | $1,950 |
| 2021-05 | 0 | $0 | 51,301 | $2,924,335 | 10,370 | $2,652 |
| 2021-04 | 0 | $0 | 44,653 | $2,668,952 | 16,296 | $3,169 |
| 2021-03 | 0 | $0 | 53,949 | $3,243,366 | 6,300 | $2,070 |
| 2021-02 | 0 | $0 | 53,946 | $3,366,705 | 39,500 | $5,722 |
| 2020-11 | 300,000 | $15,000,000 | 0 | $0 | 0 | $0 |
| 2020-04 | 2,324,088 | $37,191,339 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-04-09 | Schneeberger Daniel | Buy | 934,258 | 9.86 | 9,212,718 |
| 2025-04-04 | Seehra Jasbir (CHIEF EXECUTIVE OFFICER) | Option Ex | 49,367 | .30 | 14,810 |
| 2024-08-13 | Orbimed Genesis Gp Llc | Sale | 250,000 | 44.01 | 11,002,500 |
| 2024-08-13 | Gordon Carl L | Sale | 250,000 | 44.01 | 11,002,500 |
| 2023-11-04 | Regnante Keith (Chief Financial Officer) | Sale | 40,000 | 45.29 | 1,811,600 |
| 2023-11-04 | Regnante Keith (Chief Financial Officer) | Option Ex | 40,000 | 16.00 | 640,000 |
| 2023-04-08 | Seehra Jasbir (Chief Executive Officer) | Option Ex | 4,000 | .48 | 1,920 |
| 2022-07-15 | Lachey Jennifer (Chief Scientific Officer) | Sale | 46,034 | 30.00 | 1,381,020 |
| 2022-07-15 | Lachey Jennifer (Chief Scientific Officer) | Option Ex | 46,034 | .30 | 13,810 |
| 2022-07-13 | Lachey Jennifer (Chief Scientific Officer) | Sale | 1,916 | 30.00 | 57,480 |
| 2022-07-13 | Lachey Jennifer (Chief Scientific Officer) | Option Ex | 1,916 | .30 | 574 |
| 2022-06-14 | Lachey Jennifer (Chief Scientific Officer) | Option Ex | 9,400 | .30 | 2,820 |
| 2022-06-09 | Seehra Jasbir (Chief Executive Officer) | Option Ex | 5,000 | .30 | 1,500 |
| 2022-05-11 | Lachey Jennifer (Chief Scientific Officer) | Sale | 5,300 | 43.35 | 229,755 |
| 2022-05-11 | Lachey Jennifer (Chief Scientific Officer) | Option Ex | 5,300 | .30 | 1,590 |
| 2022-04-11 | Lachey Jennifer (Chief Scientific Officer) | Sale | 5,300 | 62.84 | 333,025 |
| 2022-04-11 | Lachey Jennifer (Chief Scientific Officer) | Option Ex | 5,300 | .30 | 1,590 |
| 2022-04-06 | Rovaldi Christopher (Chief Operating Officer) | Sale | 1,728 | 65.00 | 112,320 |
| 2022-04-06 | Rovaldi Christopher (Chief Operating Officer) | Option Ex | 1,728 | 16.00 | 27,648 |
| 2022-04-04 | Lachey Jennifer (Chief Scientific Officer) | Sale | 7,950 | 60.00 | 477,000 |
| 2022-04-04 | Lachey Jennifer (Chief Scientific Officer) | Option Ex | 7,950 | .30 | 2,385 |
| 2022-04-01 | Rovaldi Christopher (Chief Operating Officer) | Sale | 864 | 56.85 | 49,114 |
| 2022-04-01 | Rovaldi Christopher (Chief Operating Officer) | Option Ex | 864 | 16.00 | 13,824 |
| 2022-03-11 | Lachey Jennifer (Chief Scientific Officer) | Sale | 2,650 | 53.44 | 141,623 |
| 2022-03-11 | Lachey Jennifer (Chief Scientific Officer) | Option Ex | 2,650 | .30 | 795 |
| 2022-02-11 | Lachey Jennifer (Chief Scientific Officer) | Sale | 2,650 | 52.32 | 138,640 |
| 2022-02-11 | Lachey Jennifer (Chief Scientific Officer) | Option Ex | 2,650 | .30 | 795 |
| 2022-01-11 | Lachey Jennifer (Chief Scientific Officer) | Sale | 2,650 | 53.34 | 141,351 |
| 2022-01-11 | Lachey Jennifer (Chief Scientific Officer) | Option Ex | 2,650 | .30 | 795 |
| 2022-01-05 | Knowles Julius (Director) | Sale | 4,034 | 58.14 | 234,548 |
| 2022-01-05 | Lachey Jennifer (Chief Scientific Officer) | Sale | 2,650 | 60.00 | 159,000 |
| 2022-01-05 | Lachey Jennifer (Chief Scientific Officer) | Option Ex | 2,650 | .30 | 795 |
| 2022-01-04 | Knowles Julius (Director) | Sale | 20,062 | 56.97 | 1,142,932 |
| 2022-01-03 | Knowles Julius (Director) | Sale | 23,555 | 58.25 | 1,372,125 |
| 2021-12-15 | Lachey Jennifer (Chief Scientific Officer) | Sale | 735 | 50.00 | 36,750 |
| 2021-12-15 | Lachey Jennifer (Chief Scientific Officer) | Option Ex | 735 | .30 | 220 |
| 2021-12-13 | Lachey Jennifer (Chief Scientific Officer) | Sale | 1,915 | 51.99 | 99,560 |
| 2021-12-13 | Lachey Jennifer (Chief Scientific Officer) | Option Ex | 1,915 | .30 | 574 |
| 2021-12-02 | Knowles Julius (Director) | Sale | 25,338 | 53.42 | 1,353,657 |
| 2021-12-01 | Knowles Julius (Director) | Sale | 22,313 | 55.03 | 1,227,929 |
| 2021-11-11 | Lachey Jennifer (Chief Scientific Officer) | Sale | 5,300 | 59.26 | 314,051 |
| 2021-11-11 | Lachey Jennifer (Chief Scientific Officer) | Option Ex | 5,300 | .30 | 1,590 |
| 2021-11-10 | Lachey Jennifer (Chief Scientific Officer) | Sale | 15,900 | 60.00 | 954,000 |
| 2021-11-10 | Lachey Jennifer (Chief Scientific Officer) | Option Ex | 15,900 | .30 | 4,770 |
| 2021-11-04 | Lachey Jennifer (Chief Scientific Officer) | Sale | 10,600 | 50.00 | 530,000 |
| 2021-11-04 | Lachey Jennifer (Chief Scientific Officer) | Option Ex | 10,600 | .30 | 3,180 |
| 2021-11-03 | Knowles Julius (Director) | Sale | 15,967 | 42.05 | 671,412 |
| 2021-11-02 | Knowles Julius (Director) | Sale | 7,881 | 42.57 | 335,494 |
| 2021-11-01 | Knowles Julius (Director) | Sale | 23,803 | 42.14 | 1,003,058 |
| 2021-10-20 | Knowles Julius (Director) | Sale | 4,082 | 37.93 | 154,830 |
| 2021-10-19 | Knowles Julius (Director) | Sale | 4,516 | 38.27 | 172,827 |
| 2021-10-18 | Knowles Julius (Director) | Sale | 13,786 | 38.08 | 524,901 |
| 2021-10-15 | Knowles Julius (Director) | Sale | 8,198 | 39.66 | 325,157 |
| 2021-10-14 | Knowles Julius (Director) | Sale | 4,383 | 40.13 | 175,889 |
| 2021-10-05 | Knowles Julius (Director) | Sale | 2,617 | 40.03 | 104,758 |
| 2021-10-04 | Knowles Julius (Director) | Sale | 3,746 | 40.06 | 150,064 |
| 2021-10-01 | Knowles Julius (Director) | Sale | 6,323 | 40.16 | 253,931 |
| 2021-09-27 | Knowles Julius (Director) | Sale | 95,302 | 41.44 | 3,949,314 |
| 2021-08-17 | Lachey Jennifer (Chief Scientific Officer) | Option Ex | 1,293 | .30 | 387 |
| 2021-07-02 | Knowles Julius (Director) | Sale | 23,818 | 41.40 | 986,065 |
| 2021-07-01 | Knowles Julius (Director) | Sale | 23,834 | 41.95 | 999,907 |
| 2021-06-24 | Lachey Jennifer (Chief Scientific Officer) | Option Ex | 6,500 | .30 | 1,950 |
| 2021-06-03 | Knowles Julius (Director) | Sale | 7,895 | 47.92 | 378,328 |
| 2021-06-02 | Knowles Julius (Director) | Sale | 11,529 | 49.90 | 575,239 |
| 2021-06-01 | Knowles Julius (Director) | Sale | 8,812 | 53.25 | 469,265 |
| 2021-05-13 | Lachey Jennifer (Chief Scientific Officer) | Option Ex | 6,720 | .20 | 1,377 |
| 2021-05-11 | Lachey Jennifer (Chief Scientific Officer) | Sale | 2,650 | 50.00 | 132,500 |
| 2021-05-11 | Lachey Jennifer (Chief Scientific Officer) | Option Ex | 2,650 | .30 | 795 |
| 2021-05-11 | Ordonez Claudia (Chief Medical Officer) | Sale | 1,000 | 50.15 | 50,150 |
| 2021-05-11 | Ordonez Claudia (Chief Medical Officer) | Option Ex | 1,000 | .48 | 480 |
| 2021-05-04 | Knowles Julius (Director) | Sale | 2,835 | 54.04 | 153,203 |
| 2021-05-03 | Knowles Julius (Director) | Sale | 44,816 | 57.76 | 2,588,482 |
| 2021-04-12 | Lachey Jennifer (Chief Scientific Officer) | Sale | 5,300 | 60.47 | 320,506 |
| 2021-04-12 | Lachey Jennifer (Chief Scientific Officer) | Option Ex | 5,300 | .30 | 1,590 |
| 2021-04-12 | Ordonez Claudia (Chief Medical Officer) | Sale | 1,000 | 60.11 | 60,110 |
| 2021-04-12 | Ordonez Claudia (Chief Medical Officer) | Option Ex | 1,000 | .48 | 480 |
| 2021-04-05 | Knowles Julius (Director) | Sale | 27,151 | 59.56 | 1,617,113 |
| 2021-04-01 | Knowles Julius (Director) | Sale | 11,202 | 59.92 | 671,223 |
| 2021-04-01 | Lachey Jennifer (Chief Scientific Officer) | Option Ex | 9,996 | .11 | 1,099 |
| 2021-03-11 | Lachey Jennifer (Chief Scientific Officer) | Sale | 5,300 | 64.73 | 343,053 |
| 2021-03-11 | Lachey Jennifer (Chief Scientific Officer) | Option Ex | 5,300 | .30 | 1,590 |
| 2021-03-11 | Ordonez Claudia (Chief Medical Officer) | Sale | 1,000 | 64.47 | 64,474 |
| 2021-03-11 | Ordonez Claudia (Chief Medical Officer) | Option Ex | 1,000 | .48 | 480 |
| 2021-03-04 | Knowles Julius (Director) | Sale | 11,632 | 56.17 | 653,369 |
| 2021-03-03 | Knowles Julius (Director) | Sale | 12,327 | 57.38 | 707,360 |
| 2021-03-02 | Knowles Julius (Director) | Sale | 10,711 | 59.88 | 641,353 |
| 2021-03-01 | Knowles Julius (Director) | Sale | 12,979 | 64.24 | 833,757 |
| 2021-02-26 | Lachey Jennifer (Chief Scientific Officer) | Option Ex | 33,200 | .11 | 3,652 |
| 2021-02-18 | Knowles Julius (Director) | Sale | 2,944 | 62.79 | 184,859 |
| 2021-02-17 | Knowles Julius (Director) | Sale | 16,061 | 60.78 | 976,123 |
| 2021-02-16 | Knowles Julius (Director) | Sale | 9,612 | 59.74 | 574,249 |
| 2021-02-12 | Knowles Julius (Director) | Sale | 7,468 | 62.15 | 464,121 |
| 2021-02-11 | Knowles Julius (Director) | Sale | 11,561 | 65.32 | 755,176 |
| 2021-02-11 | Lachey Jennifer (Chief Scientific Officer) | Sale | 5,300 | 65.44 | 346,805 |
| 2021-02-11 | Lachey Jennifer (Chief Scientific Officer) | Option Ex | 5,300 | .30 | 1,590 |
| 2021-02-11 | Ordonez Claudia (Chief Medical Officer) | Sale | 1,000 | 65.37 | 65,372 |
| 2021-02-11 | Ordonez Claudia (Chief Medical Officer) | Option Ex | 1,000 | .48 | 480 |
| 2020-11-17 | Pontifax Late Stage Gp Ltd. (10% Owner) | Buy | 180,000 | 50.00 | 9,000,000 |
| 2020-04-13 | Orbimed Genesis Gp Llc (Director) | Buy | 375,200 | 16.00 | 6,003,200 |
| 2020-04-13 | Knowles Julius (Director) | Buy | 1,191 | 20.98 | 24,987 |
| 2020-04-13 | Lazarus Alon (Director) | Buy | 120,000 | 16.00 | 1,920,000 |
| 2020-04-13 | Pontifax Late Stage Gp Ltd. (10% Owner) | Buy | 437,499 | 16.00 | 6,999,984 |
| 2020-04-13 | Seehra Jasbir (Chief Executive Officer) | Buy | 20,000 | 16.00 | 320,000 |
| 2020-04-13 | Nussbaum Ran (Director) | Buy | 437,499 | 16.00 | 6,999,984 |
| 2020-04-13 | Kariv Tomer (Director) | Buy | 437,499 | 16.00 | 6,999,984 |
| 2020-04-13 | Arkin Moshe | Buy | 120,000 | 16.00 | 1,920,000 |
| 2020-04-13 | Gordon Carl L (Director) | Buy | 375,200 | 16.00 | 6,003,200 |
Insider trading activities including stock purchases, stock sales, and option exercises of KROS listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Keros Therapeutics, Inc. (symbol KROS, CIK number 1664710) see the Securities and Exchange Commission (SEC) website.